PURPOSE: The aim of the present study was to determine the profile of mismatch repair (MMR) defects in Iranian colorectal cancer patients by using immunohistochemical staining for products of four MMR genes: MLH1, MSH2, PMS2, and MSH6. METHODS: Tissue samples of 343 patients were immunostained for MLH1, MSH2, PMS2, and MSH6. Clinical and family history and survival data were compared between normal and abnormal staining patterns. RESULTS: Fourteen percent of the patients had abnormal nuclear staining for MMR proteins. MLH1 was absent in four, MLH1/PMS2 in 15, PMS2 in five, MSH2 in 12, and MSH2/MSH6 in 12 patients. These tumors were more proximal, had a nonsignificant better survival, and were more associated with positive family history. Estimation of this study of prevalence of hereditary nonpolyposis colorectal cancer in Iran was 5.5% of the total colorectal cancers. CONCLUSIONS: Along with the recommendations of the National Institute of Cancer, we recommend immunohistochemistry staining for MLH1, MSH2, PMS2, and MSH6 for determining the eligibility of patients for mutation analysis of MMR genes.
PURPOSE: The aim of the present study was to determine the profile of mismatch repair (MMR) defects in Iranian colorectal cancerpatients by using immunohistochemical staining for products of four MMR genes: MLH1, MSH2, PMS2, and MSH6. METHODS: Tissue samples of 343 patients were immunostained for MLH1, MSH2, PMS2, and MSH6. Clinical and family history and survival data were compared between normal and abnormal staining patterns. RESULTS: Fourteen percent of the patients had abnormal nuclear staining for MMR proteins. MLH1 was absent in four, MLH1/PMS2 in 15, PMS2 in five, MSH2 in 12, and MSH2/MSH6 in 12 patients. These tumors were more proximal, had a nonsignificant better survival, and were more associated with positive family history. Estimation of this study of prevalence of hereditary nonpolyposis colorectal cancer in Iran was 5.5% of the total colorectal cancers. CONCLUSIONS: Along with the recommendations of the National Institute of Cancer, we recommend immunohistochemistry staining for MLH1, MSH2, PMS2, and MSH6 for determining the eligibility of patients for mutation analysis of MMR genes.
Authors: L Cawkwell; S Gray; H Murgatroyd; F Sutherland; L Haine; M Longfellow; S O'Loughlin; D Cross; O Kronborg; C Fenger; N Mapstone; M Dixon; P Quirke Journal: Gut Date: 1999-09 Impact factor: 23.059
Authors: J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau Journal: Cancer Res Date: 1998-08-01 Impact factor: 12.701
Authors: H R Yun; L J Yi; Y K Cho; J H Park; Y B Cho; S H Yun; H C Kim; H K Chun; W Y Lee Journal: Int J Colorectal Dis Date: 2008-09-17 Impact factor: 2.571
Authors: C I Müller; K Schulmann; A Reinacher-Schick; N Andre; D Arnold; A Tannapfel; H Arkenau; S A Hahn; S H-J Schmoll; R Porschen; W Schmiegel; U Graeven Journal: Int J Colorectal Dis Date: 2008-07-02 Impact factor: 2.571
Authors: L A Aaltonen; P Peltomäki; J P Mecklin; H Järvinen; J R Jass; J S Green; H T Lynch; P Watson; G Tallqvist; M Juhola Journal: Cancer Res Date: 1994-04-01 Impact factor: 12.701
Authors: Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa Journal: Fam Cancer Date: 2010-06 Impact factor: 2.375
Authors: George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis M Giardiello Journal: Fam Cancer Date: 2021-01-11 Impact factor: 2.375
Authors: George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis Giardiello Journal: Fam Cancer Date: 2020-09-11 Impact factor: 2.375